Table 1. Baseline characteristics of KTRs.
| Variables | Control (n = 141) | De novo anti-HLA Ab (+) DSA (+) (n = 16) | De novo anti-HLA Ab (+) DSA (−) (n = 10) | P valuea | P valueb | |
|---|---|---|---|---|---|---|
| Age, yr | 45.6 ± 12.8 | 48.5 ± 13.6 | 50.5 ± 8.4 | 0.396 | 0.236 | |
| Sex, male | 104 (73.8) | 14 (87.5) | 7 (70.0) | 0.361 | 0.725 | |
| Primary kidney disease | 0.590 | 0.668 | ||||
| Diabetes | 40 (28.4) | 4 (25.0) | 5 (50.0) | |||
| Hypertension | 11 (7.8) | 2 (12.5) | 0 (0) | |||
| CGN | 79 (56.0) | 9 (56.3) | 5 (50) | |||
| Cystic disease | 3 (2.1) | 1 (6.3) | 0 (0) | |||
| Others | 8 (5.7) | 0 (0) | 0 (0) | |||
| Type of transplant donor | 1.000 | 0.848 | ||||
| Living related | 45 (31.9) | 5 (31.3) | 3 (30.0) | |||
| Living unrelated | 41 (29.1) | 5 (31.3) | 2 (30.0) | |||
| Deceased | 55 (39.0) | 6 (37.5) | 5 (50.0) | |||
| HLA mismatch | ||||||
| Total | 3.3 ± 1.6 | 3.2 ± 1.1 | 2.5 ± 1.8 | 0.796 | 0.118 | |
| DR | 1.1 ± 0.7 | 1.3 ± 0.5 | 0.6 ± 0.7 | 0.469 | 0.018 | |
| ABOi KT | 15 (10.6) | 1 (6.3) | 0 (0) | 1.000 | 0.599 | |
| Desensitization | 15 (10.6) | 1 (6.3) | 0 (0) | 1.000 | ||
| Induction therapy | ||||||
| IL-2 receptor blocker | 141 (100) | 16 (100) | 10 (100) | |||
| Maintenance immunosuppressant | 0.194 | 0.128 | ||||
| TAC | 140 (99.3) | 15 (93.8) | 9 (90.0) | |||
| Cyclosporine | 1 (0.7) | 1 (6.3) | 1 (10.0) | |||
| Mycophenolic acid | 141 (100) | 16 (100) | 10 (100) | |||
| Methylprednisolone | 141 (100) | 16 (100) | 10 (100) | |||
| TAC trough levels, ng/mL | ||||||
| 0–2 mon | 7.53 ± 1.79 | 6.63 ± 1.24 | 5.76 ± 1.82 | 0.052 | 0.003 | |
| 3–6 mon | 6.31 ± 1.70 | 5.27 ± 1.43 | 4.94 ± 1.84 | 0.020 | 0.015 | |
| 7–12 mon | 5.87 ± 1.62 | 4.82 ± 2.03 | 4.71 ± 1.73 | 0.018 | 0.032 | |
| CV (%) | 22.3 ± 12.2 | 24.8 ± 15.9 | 18.9 ± 7.4 | 0.449 | 0.394 | |
Values are shown as mean ± standard deviation (range) or number (%).
Ab = antibodies, ABOi = ABO incompatible, CGN = chronic glomerulonephritis, CV = coefficient of variation, DSA = donor-specific anti-human leukocyte antigens antibodies, HLA = human leukocyte antigens, IL = interleukin, KT = kidney transplantation, KTRs = kidney transplant recipients, TAC = tacrolimus.
aSignificance of the difference between control and de novo anti-HLA Ab (+) DSA (+); bSignificance of the difference between control and de novo anti-HLA Ab (+) DSA (−).